Abstract:Topoisomerase II is a key target for several anti-cancer drugs used for breast cancer therapy, including doxorubicin, epirubicin and mitoxantrone. Two isoforms of topoisomerase II (alpha and beta) have been described in human cells which differ in their subcellular localisation, biochemical properties and susceptibility to inhibition by anti-cancer drugs. The relative level of expression of the alpha and beta isoforms may contribute to the degree of tumour responsiveness to different chemotherapeutic agents. To assess the relationship between expression of topoisomerase II isoforms and established prognostic factors and pathological variables, 56 primary breast tumour samples were studied. The expression of the two topoisomerase II genes was apparently not co-ordinately regulated in these tissue samples. There was no relationship between any of the commonly used pathological variables [tumour size, lymph node status, S-phase fraction (SPF)] and the level of expression of topoisomerase II beta mRNA. However, high topoisomerase II alpha gene expression was significantly associated with a high SPF (sign-rank test; P = 0.01). Moreover, the ratio of mRNA levels for topoisomerase II alpha and beta showed a stronger relationship to SPF (median raito 0.62 for tumours with SPF < 10, and 1.64 for SPF > 10; P = 0.0021, sign-rank test). As expected from previous studies, an SPF > 10 was associated with poor overall survival (P = 0.01). Immunohistochemical analysis revealed that topoisomerase II beta was widely distributed ( > 90% positive tumour cells), but that topoisomerase II alpha expression was less widely expressed, with a pattern of expression similar to that of the proliferation-dependent antigen recognised by Ki67. Because topoisomerase II gene expression showed a log-normal distribution, log-transformed data were used in multivariate analysis of relapse-free survival. This showed that lymph node status and topoisomerase II beta mRNA expression were the only significant survival factors (P = 0.001 and 0.05, respectively, with relative risks of 1.3 and 1.8). These results indicate that topoisomerase II alpha, but not beta, expression is dependent upon cellular proliferation status, but that the more widely expressed topoisomerase II beta protein may play a significant role as a target for anti-tumour therapy.

Human Cells Express Two Differentially Spliced Forms of Topoisomerase IIβ Mrna

Isolation of Cdna Clones Encoding the Β Isozyme of Human DNA Topoisomerase II and Localisation of the Gene to Chromosome 3P24

The Distribution and Expression of the Two Isoforms of DNA Topoisomerase II in Normal and Neoplastic Human Tissues.

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

Differential Expression of the Topoisomerase IIα and Β Genes in Human Breast Cancers

Relationship Between Expression of Topoisomerase II Isoforms and Intrinsic Sensitivity to Topoisomerase II Inhibitors in Breast Cancer Cell Lines

Identification of Alternative Splicing Variants of the Beta Subunit of Human Ca(2+)/calmodulin-dependent Protein Kinase II with Different Activities.

Cloning and characterization of the 5'-flanking region of the human topoisomerase II alpha gene.

Identification and Expression Analysis of a Novel Splice Variant of Human Tumor Necrosis Factor Receptor Associated Factor 2

Human DNA Topoisomerases IIα and IIβ Can Functionally Substitute for Yeast TOP2 in Chromosome Segregation and Recombination

Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells

Human Topoisomerase II Alpha is Phosphorylated in a Cell-Cycle Phase-Dependent Manner by a Proline-Directed Kinase.

Regulation of the Human Topoisomerase IIα Gene Promoter in Confluence-arrested Cells

Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.

Topoisomerase IIβ targets DNA crossovers formed between distant homologous sites to modulate chromatin structure and gene expression

Topoisomerase IIβ targets DNA crossovers formed between distant homologous sites to induce chromatin opening

Molecular Analysis of a Potentially Phorbol-Regulatable Region of the Human Topoisomerase IIα Gene Promoter

Molecular analysis of a potentially phorbol-regulatable region of the human topoisomerase II alpha gene promoter.

Cell Cycle Phase-specific Phosphorylation of Human Topoisomerase IIα

Bioinformatic Analysis of Topoisomerase IIα Reveals Interdomain Interdependencies and Critical C-Terminal Domain Residues

Mutations in topoisomerase IIβ result in a B cell immunodeficiency